Mineralys makes money moves before looming hypertension approval

Jon Congleton, Mineralys Therapeutics CEO June 3, 2026 10:32 AM EDT Financing Min­eralys makes mon­ey moves be­fore loom­ing hy­per­ten­sion ap­proval Kyle LaHucik Biotech Correspondent Min­eralys Ther­a­peu­tics first drew at­ten­tion in 2021 with a bold bet on a new type of hy­per­ten­sion drug called lorun­dro­stat. It came with a tiny … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER